Cytek Biosciences
CTKB
102 hedge funds and large institutions have $630M invested in Cytek Biosciences in 2023 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 41 increasing their positions, 34 reducing their positions, and 17 closing their positions.
92,700% more call options, than puts
Call options by funds: $928K | Put options by funds: $1K
21% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 34
3.08% more ownership
Funds ownership: 47.5% → 50.59% (+3.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less funds holding
Funds holding: 103 → 102 (-1)
4% less capital invested
Capital invested by funds: $654M → $630M (-$24.5M)
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$37.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.3M |
| 3 |
Millennium Management
New York
|
+$8.79M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$7.21M |
| 5 |
New York State Common Retirement Fund
Albany,
New York
|
+$5.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$10.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.3M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$4.3M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.98M |
| 5 |
MGM
Miura Global Management
New York
|
-$3.7M |
CTKB Hedge Fund Activity: Q1 2023 in Review
102 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q1 2023, worth a combined $630M — down 3.7% from $654M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CTKB and 16 opened new positions — a net loss of 1 holder — while 34 trimmed existing stakes and 41 added.
The largest buyer was Brown Capital Management, adding an estimated $37.6M. The largest seller was HHLR Advisors, cutting an estimated $10.6M.
- 102 institutional investors held Cytek Biosciences (CTKB) as of Q1 2023, down from 103 in Q4 2022.
- Funds reported $630M of Cytek Biosciences stock for Q1 2023, down 3.7% quarter-over-quarter.
- 16 funds opened new Cytek Biosciences positions in Q1 2023 and 17 closed out, a net change of -1 holder.
- The largest Cytek Biosciences buyer in Q1 2023 was Brown Capital Management, an estimated $37.6M added.
- The largest Cytek Biosciences seller in Q1 2023 was HHLR Advisors, an estimated $10.6M sold.
Based on aggregated 13F filings for Q1 2023.